Analysts expect that Sientra (NASDAQ:SIEN) will report sales of $15.30 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sientra’s earnings. The highest sales estimate is $15.60 million and the lowest is $14.90 million. Sientra posted sales of $8.17 million during the same quarter last year, which suggests a positive year-over-year growth rate of 87.3%. The business is expected to issue its next earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Sientra will report full-year sales of $65.80 million for the current year, with estimates ranging from $65.10 million to $67.00 million. For the next financial year, analysts forecast that the company will post sales of $95.03 million per share, with estimates ranging from $90.30 million to $99.30 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Sientra.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Wednesday, May 9th. The medical instruments supplier reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.15). Sientra had a negative net margin of 164.72% and a negative return on equity of 181.25%. The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $14.49 million. During the same quarter in the previous year, the business posted $0.61 EPS. Sientra’s revenue for the quarter was up 95.2% compared to the same quarter last year.

A number of research analysts recently commented on the stock. Canaccord Genuity reiterated a “buy” rating and set a $19.00 price objective on shares of Sientra in a research note on Thursday, May 10th. ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Maxim Group raised their price objective on shares of Sientra from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, April 26th. Zacks Investment Research upgraded shares of Sientra from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 24th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Sientra in a research note on Friday, April 20th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Sientra has a consensus rating of “Buy” and a consensus price target of $15.17.

NASDAQ SIEN opened at $16.74 on Thursday. Sientra has a 12 month low of $16.61 and a 12 month high of $16.98. The company has a current ratio of 1.21, a quick ratio of 0.71 and a debt-to-equity ratio of 2.31. The company has a market cap of $330.96 million, a P/E ratio of -5.94 and a beta of -1.11.

In other Sientra news, Chairman Jeffrey M. Nugent purchased 1,852 shares of the firm’s stock in a transaction on Monday, May 7th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $25,002.00. Following the completion of the transaction, the chairman now owns 299,851 shares in the company, valued at approximately $4,047,988.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Timothy Haines purchased 281,482 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was acquired at an average price of $13.50 per share, for a total transaction of $3,800,007.00. Following the transaction, the insider now owns 31,546 shares of the company’s stock, valued at approximately $425,871. The disclosure for this purchase can be found here. Insiders have purchased 301,853 shares of company stock worth $4,075,016 in the last quarter. Company insiders own 31.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Monarch Partners Asset Management LLC acquired a new position in Sientra in the first quarter worth approximately $258,000. Barclays PLC grew its position in Sientra by 133.7% in the first quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 18,033 shares during the last quarter. Wells Fargo & Company MN grew its position in Sientra by 175.2% in the third quarter. Wells Fargo & Company MN now owns 22,903 shares of the medical instruments supplier’s stock worth $353,000 after buying an additional 14,582 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Sientra in the fourth quarter worth approximately $391,000. Finally, Two Sigma Investments LP grew its position in Sientra by 120.1% in the fourth quarter. Two Sigma Investments LP now owns 32,382 shares of the medical instruments supplier’s stock worth $455,000 after buying an additional 17,668 shares during the last quarter. Hedge funds and other institutional investors own 77.69% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.